Evaluation of Clinical Significance of Circulating Markers in Breast Cancer Patients Undergoing Herceptin [trastuzumab] Therapy.
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 08 Jul 2015
At a glance
- Drugs Trastuzumab (Primary)
- Indications Breast cancer
- Focus Biomarker; Therapeutic Use
- Acronyms HER2
- 31 Aug 2018 Biomarkers information updated
- 18 Jan 2012 Additional lead trial investigator (Kangerloo B) identified as reported by ClinicalTrials.gov.
- 18 Jan 2012 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.